A safety group asked the FDA to block compounding of seven peptides — including MOTS-c
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
In July, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in favor of allowing six of seven contested peptides to be compounded, against the recommendation of the agency's own scientists. This week the Partnership for Safe Medicines (PSM) asked the FDA, formally and on the record, not to follow that vote.
What exactly does the petition ask for?
Two actions: block compounding of these peptides by any route, and set aside the advisory committee vote on grounds that the committee was constituted in violation of the Federal Advisory Committee Act (FACA) and the Ethics in Government Act (EIGA), the federal laws governing conflicts of interest in agency advisory proceedings. PSM says the committee's newly appointed members include individuals with financial ties to the peptide industry.
What is the safety case, in the petition's own terms?
Executive Director Shabbir Imber Safdar: 'FDA scientists reviewed these substances and found no adequate characterization, extremely limited safety data, and no meaningful human evidence. Legitimizing these compounds doesn't make them safer. It just makes them easier to sell.' For MOTS-c readers, that 'no meaningful human evidence' line is the contested point in miniature: the mitochondria-derived peptide has intriguing animal and early research data, which this site covers, and no completed human efficacy trials establishing dose, safety or benefit for compounded use.
What happens next — and what does not change today?
A citizen petition does not change the law by itself; it obliges the FDA to respond on the record. Compounding access, interim policies and the July vote's weight all remain in the agency's hands, in a debate where patient-access advocates and the MAHA movement have pushed the other direction. Nothing in the petition bans anything today. What it does is force the conflict-of-interest and characterization questions into the FDA's formal reply — and readers buying any of these peptides should know that fight is now explicit.
Frequently asked questions
What is the Partnership for Safe Medicines asking the FDA to do?
In a citizen petition filed October 21, 2026, the group asked the FDA to block compounding of seven peptides — BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon — and to set aside a July advisory committee vote that recommended allowing six of the seven.
Why does the petition challenge the advisory committee vote?
The petition argues the Pharmacy Compounding Advisory Committee was constituted in violation of federal conflict-of-interest laws — the Federal Advisory Committee Act and the Ethics in Government Act — saying newly appointed members include individuals with financial ties to the peptide industry. The FDA has not adjudicated those allegations.
Which peptide on the list is mitochondria-related?
MOTS-c. It is a mitochondria-derived peptide with intriguing animal and early research data, but no completed human efficacy trials establishing dose, safety or benefit for compounded use.
Does the petition ban these peptides today?
No. A citizen petition does not change the law by itself; it obliges the FDA to respond on the record. Compounding access and the weight of the July vote remain in the agency's hands.
Where the evidence stands
- Established: At the July PCAC meeting, FDA scientists recommended against bulk compounding of BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon, while the committee voted to allow six of the seven; none of the seven is an FDA-approved drug.
- Contested: PSM's October 21, 2026 citizen petition asks FDA to block compounding of all seven and disregard the PCAC vote, alleging FACA/EIGA violations and industry-tied committee members — allegations the FDA has not adjudicated and access advocates dispute in the wider debate.
- Absent: Meaningful human safety and efficacy evidence for compounded use of these peptides, per the FDA scientists quoted in the petition, and an FDA decision on the petition itself.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.